Back to results
US 2024/0122978 A1Published application
Retroviral vector for univeral receptor therapy
AssigneeUmoja Biopharma, Inc.
InventorAndrew SCHARENBERG
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to retroviral vectors comprising polynucleotides encoding hapten-binding receptors and T cell activating receptors. The retroviral vectors may also comprise transduction enhancers. Also disclosed are adaptor molecules and their use in conjunction with the retroviral vectors and T cells transduced with the retroviral vectors.
Claims89
A method, comprising:
- (a) administering to a subject an adaptor molecule comprising a targeting moiety and a hapten;
- and
- (b) administering to the subject either (i) a plurality of recombinant retroviral particles or (ii) immune cells that have been contacted ex vivo with a plurality of recombinant retroviral particles,
- wherein each of the retroviral particles comprises a polynucleotide comprising a sequence encoding a receptor that specifically binds to the hapten;
- and
- wherein each of the retroviral particles comprises a viral envelope.
3 more elements
A system, therapeutic system, or composition, comprising:
- (a) an adaptor molecule comprising a targeting moiety and a masked hapten, wherein the masked hapten comprises a masking moiety linked to a hapten;
- and
- (b) a plurality of recombinant retroviral particles,
- wherein each of the retroviral particles comprises a polynucleotide comprising, in 5′ to 3′ order:
- (i) a 5′ UTR,
- (ii) a promoter,
- (iii) a sequence encoding a receptor that specifically binds to the hapten, and
- (iv) a 3′ UTR;
- and
- wherein each of the retroviral particles comprises a viral envelope comprising
- (i) a cell-surface receptor, and
- (ii) one or more transduction enhancers
- wherein optionally each of the transduction enhancers is selected from the group consisting of a T-cell activation receptor, a NK-cell activation receptor, and a co-stimulatory molecule.
10 more elements
A retroviral particle, comprising
- (a) a polynucleotide comprising, in 5′ to 3′ order:
- (i) a 5′ LTR or UTR,
- (ii) a promoter,
- (iii) a sequence encoding a receptor that specifically binds to the hapten, and
- (iv) a 3′ LTR or UTR;
- and
- (b) a viral envelope comprising
- (i) a cell-surface receptor, and
- (ii) one or more transduction enhancers;
- and
- wherein optionally each of the transduction enhancers is a T-cell activation receptor, a NK-cell activation receptor, or a co-stimulatory molecule.
8 more elements
Dependencies are inferred from the claim text.